12 completed, 3 recruiting, 1 terminated, 1 unknown. 18 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 12, Recruiting 3, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Biomedical Advanced Research And Development Authority: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet - Invasive Mold Infections | Phase 3 | Recruiting | Basilea Pharmaceutica | 234 | 2025-08-26 | 2026-10-28 |
| Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP Cefepime-taniborbactam, Meropenem - Ventilator-associated Pneumonia, Hospital-acquired Pneumonia | Phase 3 | Withdrawn | Venatorx Pharmaceuticals, Inc. | 2025-06-01 | 2025-06-08 | |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA) - Hemorrhagic Shock, Trauma Injury | Phase 3 | Recruiting | Philip Spinella | 1000 | 2024-11-01 | 2026-09-17 |
| StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects StrataGraft - Skin Wound, Burns | Phase 3 | Completed | Stratatech, a Mallinckrodt Company | 1 | 2023-04-28 | 2025-03-18 |
| Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia Ramatroban, Placebo - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Phase 2 / Phase 3 | Unknown | KARE Biosciences | 324 | 2022-11-10 | 2023-01-31 |
| A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 mRNA-1273, Placebo, mRNA-1273.222 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 4328 | 2020-12-09 | 2025-09-15 |
| Immune Modulators for Treating COVID-19 Infliximab, Abatacept, Remdesivir - Covid19 | Phase 3 | Completed | Daniel Benjamin | 1971 | 2020-10-15 | 2023-09-25 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 mRNA-1273, Placebo - SARS-CoV-2 | Phase 3 | Completed | ModernaTX, Inc. | 30415 | 2020-07-27 | 2024-03-21 |
| Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial FD MVA-BN - Smallpox | Phase 3 | Completed | Bavarian Nordic | 1129 | 2019-06-19 | 2021-05-27 |
| VELOCITY: An Anthrax Vaccine Clinical Study AV7909, BioThrax - Anthrax | Phase 3 | Completed | Emergent BioSolutions | 3689 | 2019-03-11 | 2026-05-06 |
| Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Ceftobiprole medocaril, Daptomycin - Staphylococcus Aureus Bacteremia | Phase 3 | Completed | Basilea Pharmaceutica | 390 | 2018-08-26 | 2026-10-07 |
| A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. ATM-AVI, MTZ, MER - Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia | Phase 3 | Completed | Pfizer | 422 | 2018-04-05 | 2024-12-10 |
| Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections ceftobiprole medocaril, vancomycin+aztreonam - Acute Bacterial Skin and Skin Structure Infections | Phase 3 | Completed | Basilea Pharmaceutica | 679 | 2018-02-19 | 2026-09-18 |
| A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age aH5N1c, Placebo - Avian Influenza | Phase 3 | Completed | Seqirus | 3196 | 2016-07-11 | 2024-12-06 |
| Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia Solithromycin, Standard of Care - Community-acquired Bacterial Pneumonia | Phase 2 / Phase 3 | Terminated | Melinta Therapeutics, Inc. | 97 | 2016-04-01 | 2019-01-03 |
| Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections AB103 0.5 mg/kg, NaCl 0.9% - Necrotizing Soft Tissue Infections, Necrotizing Fasciitis | Phase 3 | Completed | Atox Bio Ltd | 290 | 2015-12-01 | 2021-10-05 |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat tecovirimat, Placebo - Smallpox | Phase 3 | Completed | SIGA Technologies | 449 | 2015-06-19 | 2026-09-11 |
COVID-19 (4) · Coronavirus Infections (2) · Mycoses (2) · Pneumonia, Ventilator-Associated (2) · Smallpox (2) · Virus Diseases (2) · Accidental Injuries (1) · Anthrax (1) · Bacteremia (1) · Burns (1) · Candidemia (1) · Candidiasis, Invasive (1) · Fasciitis, Necrotizing (1) · Fournier Gangrene (1) · Healthcare-Associated Pneumonia (1)
2019-nCoV Vaccine mRNA-1273 (2) · ceftobiprole medocaril (2) · AB103 (1) · Abatacept (1) · Amoxicillin (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Ampicillin (1) · Azithromycin (1) · Biothrax (1) · Caspofungin (1) · Ceftriaxone (1) · Daptomycin (1) · Erythromycin (1) · Fluconazole (1) · Infliximab (1)
United States (16) · Bulgaria (5) · Spain (5) · Argentina (4) · Greece (4) · Israel (4) · Italy (4) · Brazil (3) · France (3) · Germany (3) · Mexico (3) · Taiwan (3) · Thailand (3) · Ukraine (3) · Australia (2)
Marc Engelhardt, MD (2) · Ajay Gupta, MD (1) · Alexandra Hill, MD (1) · Alison Kuchta, MD (1) · Bill Powderly, MD (1) · Daniel K Benjamin, MD, PhD (1) · Deanna J Nelson, PhD (1) · Dennis Hruby, Ph.D. (1) · Edgar T Overton, MD (1) · Eileen M Bulger, MD (1) · Gideon Akintunde, MD (1) · Martin Ogletree, PhD (1) · Michael Cohen-Wolkowiez, MD, PhD (1)
PMID 29972742, PMID 32657946, PMID 32897367, PMID 33378609, PMID 33960817, PMID 34379915, PMID 34401888, PMID 34473343, PMID 34551225, PMID 35145311, PMID 35455245, PMID 35535503, PMID 35785530, PMID 36055877, PMID 36172138, PMID 36202997, PMID 36203544, PMID 36460535, PMID 37075127, PMID 37330602, PMID 37385888, PMID 37428480, PMID 37754204, PMID 38252170, PMID 38662372, PMID 39209823, PMID 39225478, PMID 39261482, PMID 39332418, PMID 39389071, PMID 39610848, PMID 39679349, PMID 39898869, PMID 40530972, PMID 40838594, PMID 41269522, PMID 41369204, PMID 41401704, PMID 41622397
2017 (1), 2023 (1)